The University of Chicago Header Logo

Connection

Michael H. Davidson to Aged, 80 and over

This is a "connection" page, showing publications Michael H. Davidson has written about Aged, 80 and over.
Connection Strength

0.989
  1. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clin Colorectal Cancer. 2018 09; 17(3):223-230.
    View in: PubMed
    Score: 0.077
  2. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.051
  3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.043
  4. Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008 Apr 01; 101(7):986-91.
    View in: PubMed
    Score: 0.037
  5. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81.
    View in: PubMed
    Score: 0.037
  6. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005 Jun; 24(3):189-99.
    View in: PubMed
    Score: 0.031
  7. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
    View in: PubMed
    Score: 0.030
  8. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.029
  9. Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: a cross-sectional study. Arch Gerontol Geriatr. 2004 Jan-Feb; 38(1):61-8.
    View in: PubMed
    Score: 0.028
  10. Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. Int J Vitam Nutr Res. 2003 Oct; 73(5):357-68.
    View in: PubMed
    Score: 0.028
  11. Perceived patient threat and neuroleptic dosage. J Nerv Ment Dis. 2003 Feb; 191(2):129-30.
    View in: PubMed
    Score: 0.027
  12. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
    View in: PubMed
    Score: 0.026
  13. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
    View in: PubMed
    Score: 0.022
  14. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr. 1998 Mar; 67(3):367-76.
    View in: PubMed
    Score: 0.019
  15. Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. J Am Coll Nutr. 1997 Dec; 16(6):578-83.
    View in: PubMed
    Score: 0.019
  16. The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997 Oct 30; 27(2-3):211-8.
    View in: PubMed
    Score: 0.018
  17. Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Int J Geriatr Psychiatry. 1997 Oct; 12(10):1001-7.
    View in: PubMed
    Score: 0.018
  18. Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
    View in: PubMed
    Score: 0.018
  19. Verbal fluency deficits in geriatric and nongeriatric chronic schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997; 9(4):584-90.
    View in: PubMed
    Score: 0.017
  20. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res. 1996 Dec 15; 22(3):223-31.
    View in: PubMed
    Score: 0.017
  21. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996 Oct; 23(5 Suppl 12):40-7.
    View in: PubMed
    Score: 0.017
  22. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 04; 334(1):1-6.
    View in: PubMed
    Score: 0.016
  23. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
    View in: PubMed
    Score: 0.016
  24. Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment. Schizophr Res. 1995 Sep; 17(1):15-24.
    View in: PubMed
    Score: 0.016
  25. The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry. 1995 May; 166(5):630-3.
    View in: PubMed
    Score: 0.015
  26. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995 Feb; 152(2):197-207.
    View in: PubMed
    Score: 0.015
  27. Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J Neuropsychiatry Clin Neurosci. 1995; 7(2):207-12.
    View in: PubMed
    Score: 0.015
  28. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med. 1994 Oct 10; 154(19):2209-14.
    View in: PubMed
    Score: 0.015
  29. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015 Feb 14; 36(7):449-56.
    View in: PubMed
    Score: 0.015
  30. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
    View in: PubMed
    Score: 0.014
  31. Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol. 2013 Nov; 37(7):751-7.
    View in: PubMed
    Score: 0.014
  32. Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. Schizophr Bull. 1993; 19(4):723-32.
    View in: PubMed
    Score: 0.013
  33. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
    View in: PubMed
    Score: 0.013
  34. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab. 2012 Jan; 97(1):E110-4.
    View in: PubMed
    Score: 0.012
  35. Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg. 2010 Jan; 89(1):72-80; discussion p 80.
    View in: PubMed
    Score: 0.011
  36. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
    View in: PubMed
    Score: 0.011
  37. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.010
  38. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA. 1989 Feb 03; 261(5):715-8.
    View in: PubMed
    Score: 0.010
  39. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009; 29(4):215-29.
    View in: PubMed
    Score: 0.010
  40. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 06; 296(21):2572-81.
    View in: PubMed
    Score: 0.009
  41. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
    View in: PubMed
    Score: 0.008
  42. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
    View in: PubMed
    Score: 0.008
  43. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005 Nov; 13(11):991-8.
    View in: PubMed
    Score: 0.008
  44. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism. 2005 Jul; 54(7):939-46.
    View in: PubMed
    Score: 0.008
  45. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
    View in: PubMed
    Score: 0.008
  46. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15; 92(2):152-60.
    View in: PubMed
    Score: 0.007
  47. Validation of the modified telephone interview for cognitive status (TICS-m) in Hebrew. Int J Geriatr Psychiatry. 2003 May; 18(5):381-6.
    View in: PubMed
    Score: 0.007
  48. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
    View in: PubMed
    Score: 0.007
  49. A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
    View in: PubMed
    Score: 0.007
  50. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002 Apr-Jun; 16(2):73-80.
    View in: PubMed
    Score: 0.006
  51. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
    View in: PubMed
    Score: 0.006
  52. Assessing health status quality of life in ALS: comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health Survey. ALS C.A.R.E. Study Group. Clinical Assessement, Research, and Education. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Mar; 2(1):31-7.
    View in: PubMed
    Score: 0.006
  53. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
    View in: PubMed
    Score: 0.005
  54. Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). Eur J Hum Genet. 1998 Mar-Apr; 6(2):176-80.
    View in: PubMed
    Score: 0.005
  55. Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives. Int J Cancer. 1997 Apr 10; 71(2):218-22.
    View in: PubMed
    Score: 0.004
  56. Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997; 23(1):131-45.
    View in: PubMed
    Score: 0.004
  57. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
    View in: PubMed
    Score: 0.004
  58. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma. 1995 Jun; 18(1-2):145-52.
    View in: PubMed
    Score: 0.004
  59. Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci. 1995; 7(1):76-81.
    View in: PubMed
    Score: 0.004
  60. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
    View in: PubMed
    Score: 0.004
  61. Myocardial viability in asynergic regions subtended by occluded coronary arteries: relation to the status of collateral flow in patients with chronic coronary artery disease. J Am Coll Cardiol. 1994 Mar 15; 23(4):860-8.
    View in: PubMed
    Score: 0.004
  62. Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
    View in: PubMed
    Score: 0.003
  63. Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992 May; 42(2):101-10.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.